Categorized | Featured, Long Ideas

Amedisys Rallies Ahead of Earnings

Amedisys Inc. (AMED)Amedisys Inc. (AMED) has had a challenging year so far.  The home healthcare provider has seen its stock cut nearly in half from its high in February, and while many stocks were enjoying triple digit gains off their March lows, Amedisys simply made up about 50% of its decline.  Still, the company is on solid footing and appears to be building a foundation which could lead to siginificant leverage in the coming quarters.

Investment Commentary
You Can’t Afford to Miss
Sign up for the ZachStocks Newsletter:

Part of the reason Amedisys stock has been weak is investor fear over Obama’s healthcare reform plan which could significantly reduce Medicare spending in certain situations.  But many of these fears appear to be relatively unfounded as Amedisys could actually benefit from a reform to the Medicare system.  Since Amedisys actually saves Medicare money in many cases, its services could become even more valuable as Congress looks to find ways to cut costs and still deliver appropriate care.

The company’s primary business is providing in-home health care and hospice services to acute patients.  As technology advances, it is becoming easier to provide quality service in the home with a few key side benefits.  First, there is much less risk of infection when patients are treated at home.  Second, patients are more comfortable and often heal more quickly when they are treated at their own residence.  And finally, the costs associated with treating a patient at home can be significantly less than costs associated with a hospital stay where the patient is occupying a bed and using the entire resources of a hospital staff.

It’s tough to argue with the trend towards Home Health and Hospice care.  In 2006, Medicare spending for home health reached $14 billion with hospice coming in at $9.2 billion.  Those numbers are expected to reach $36 billion and $20 billion respectively in 2017 as you can see in the chart below.

Medicare Home Health and Hospice Revenue

Amedisys has proven to be a disciplined growth company and has used its resources very wisely over the past 18 months.  Coming into this period, AMED had a very strong balance sheet with low debt levels and plenty of access to capital.  During the liquidity crisis, the company was able to opportunistically buy out competing firms and expand their footprint by a large margin.  Making these acquisitions at an opportunistic time allows the company to grow their revenue base very quickly, while still keeping their costs relatively low.

While acquisitions have played a big part in the company’s recent expansion, management is committed to starting up new offices in areas where they can see a strong return on investment.  Typically it costs $250,000 to $350,000 to open a new location and it takes about 18 months to recoup that cost.  By the end of the second year of operations, a typical start-up will generate $1.5 to $2.0 million in reveune.  So it is clear that these start-up locations can have a strong impact on earnings in the coming quarters.  In 2009, the company has set a goal of opening 40 home health locations and 5 hospice locations which will likely begin generating profit in late 2010 and early 2011.

Amedisys receives referrals from both hospitals and individual physicians.  However, compared to the national norms, the company recieves a greater weighting of physician referrals which are usually more acute situations.  According to the company’s presentation, their average patient is 82 years old, and is taking an average of 13 medications.  These patients tend to have higher Medicare reimbursement rates as the care is more intense.  This obviously leads to a more profitable business model and allows the company to provide a higher quality of treatment to those who need it most.

When considering the quality of care, Amedisys appears to be a step ahead of the curve.  The company monitors its outcomes on a number of different criteria including categories such as “Improvement in Pain, Improvement of Surgical Wounds, or Improvement in Management of Oral Meds.”  In nearly every case, Amedisys has a better score than the national average.  These results will go far in lobbying for continued Medicare support.

The stock has rallied sharply off its low in June as investors are beginning to realize the strength of Amedisys’ company as well as the reduced potential for the healthcare reform to hurt revenues.  But even after the recent 30% run, the stock still appears extremely under-valued and is trading with a single digit PE.  If the company is simply able to maintain current earnings levels, the stock would still appear relatively attractive.  But given the history of 60 to 85% increases in revenue and 45-60% increases in earnings, it appears that investors are being overly cautious.  I would expect the stock to be a great buying opportunity anywhere below $50 and possibly much higher if the company’s investments begin to generate significant cash flows.

Amedisys Inc. (AMED)

FD: Author has a long position in the ZachStocks Growth Model

Enjoy this article? Sign up for the ZachStocks Newsletter,
Your source for Sound Market Commentary, Growth Stock Analysis and Successful Investment Strategies

Amedisys Rallies Ahead of Earnings

4 Comments For This Post

  1. Littmann Stethoscope Says:

    I’m really impressed with your writing skills as well as with the layout on your blog. Is this a paid theme or did you customize it yourself? Either way keep up the nice quality writing, it’s rare to see a great blog like this one nowadays..

  2. Orpha Notaro Says:

    I’m sorry for that huge evaluation, however I’m actually loving the brand new Zune, and hope this, along with the outstanding reviews another individuals wrote, can help you decide if it is the proper selection for you.

  3. Buy WoW Gold Safe Says:

    My dear,you write very good articles,I come from GroupGold,Did you know,GroupGold Was a professional Buy WoW Gold customers trusted sites,Here you can find WoW Gold WoW Account,Here,we will give you the best service,Beloved,what can i do for you ?

  4. Govoni Says:

    thank you for helpful suggestions and merely excellent information

Leave a Reply

You must be logged in to post a comment.

Advertise Here

Loans for Bad Credit

Provident provides people with small, unsecured credit, when they need it.

Cash Loans Online

Borrow up to £500 if you are in England.

Invoice Factor Company

Hitachi Capital provides reputable and reliable invoice factoring for SMEs.

Use of Payday Loans “Robust” Across the Pond


To contact Zach email

ZachStocks Recommends:

Sell Timeshare

Charter Flights

Atlanta Bankruptcy Get Help Today!

Informative Payday loan listings

how to get a gold ira

Gold IRA

Buy Gold Coins

Buy Bullion

Buy Gold Eagle

Gold Bullion Coins

buy a gold ira

Gold Coins Investment

Penny Stock Newsletter

palladium mining

Ambit Energy Complaints -

Bad Credit Loans